Kolexia
Bonnefoi Herve Pneumologie
Bonnefoi Herve
Pneumologie
Institut Bergonié
Bordeaux, France
211 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs du sein triple-négatives Métastase tumorale Récidive tumorale locale Métastase lymphatique Cancers du sein inflammatoires Carcinome canalaire du sein Carcinomes Maladie résiduelle

Collaborateurs

Voir plus
Mac Grogan Gaetan
Mac Grogan Gaetan
Institut Bergonié, Bordeaux, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Debled Marc
Debled Marc
Institut Bergonié, Bordeaux, France

Industries

Voir plus
Pfizer
6 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2023
MSD
3 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
POLAR: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer
Essai Clinique (Pfizer)   05 mars 2024
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial.
JCO precision oncology   22 janvier 2024
SAFIR02_Breast: PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Essai Clinique (Unicancer)   09 janvier 2024
Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
Breast (Edinburgh, Scotland)   22 décembre 2023
APHINITY: A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Essai Clinique (Roche)   21 décembre 2023
SOFT: A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer
Essai Clinique (ETOP IBCSG Partners Foundation)   14 décembre 2023
TEXT: A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
Essai Clinique (ETOP IBCSG Partners Foundation)   14 décembre 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.
Nature communications   12 décembre 2023
PENELOPE-B: Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"
Essai Clinique (German Breast Group)   22 novembre 2023
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE study.
European journal of cancer (Oxford, England : 1990)   05 novembre 2023